SCHEMBL4033114

SCHEMBL4033114

CC(C)NS(=O)(=O)c1c(Cl)cccc1Cl

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 1/20 0.53
SLC1A2 P43004 1/20 0.53
LMNA P02545 2/20 0.50
PKM P14618 1/20 0.50
NR3C1 P04150 2/20 0.49
PGR P06401 1/20 0.49
NR3C2 P08235 1/20 0.49
ALDH1A1 P00352 2/20 0.46
ATM Q13315 1/20 0.46
ITGAV P06756 1/20 0.46
CNR1 P21554 1/20 0.42
CNR2 P34972 1/20 0.42
KDM4E B2RXH2 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
MCL1 Q07820 1/20 0.41
GAA P10253 1/20 0.41
SLC40A1 Q9NP59 1/20 0.41
GSTO1 P78417 1/20 0.40
HTR6 P50406 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12962556 0.81 ALDH1A1 (0.47) SLC1A3SLC1A2LMNAPKMNR3C1
SCHEMBL7409004 0.80 SLC1A3 (0.61) SLC1A3SLC1A2LMNAPKMNR3C1
SCHEMBL4031288 0.79 NR3C1 (0.52) LMNANR3C1PGRALDH1A1ITGAV
SCHEMBL12041234 0.78 SLC1A3 (0.54) SLC1A3SLC1A2LMNAPKMNR3C1
SCHEMBL16733350 0.77 NMT1 (0.49) LMNANR3C1PGRNR3C2ALDH1A1
SCHEMBL2371626 0.77 ATM (0.50) SLC1A3SLC1A2LMNAPKMNR3C1
SCHEMBL16000125 0.77 PTGES2 (0.52) LMNAALDH1A1KDM4ESMN1; SMN2SLC40A1
SCHEMBL16000104 0.77 CYP3A4 (0.55) LMNANR3C1ALDH1A1KDM4ESMN1; SMN2
SCHEMBL5184403 0.77 LMNA (0.54) SLC1A3SLC1A2LMNAPKMNR3C1
SCHEMBL6564160 0.74 ALDH1A1 (0.42) SLC1A3SLC1A2LMNAPKMNR3C1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110015185-A1 Benzofuran Compounds BIOVITRUM AB (SE) 2011-01-20 US disclosed
EP-1521744-B1 ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS FOURNIER LAB SA (FR) 2009-04-01 EP disclosed
US-7361687-B2 Arylsulphonamide derivatives and methods of preparing LABORATOIRES FOURNIER SA (FR) 2008-04-22 US disclosed
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents LABORATOIRES FOURNIER SA (FR) 2006-04-20 US disclosed
EP-1521744-A1 ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS B1 BRADYKININ RECEPTOR ANTAGONISTS LABORATOIRES FOURNIER S.A. (FR) 2005-04-13 EP disclosed
WO-2003106428-A1 NOVEL ARYLSULPHONAMIDE DERIVATIVES AND USE THEREOF AS THERAPEUTIC AGENTS LABORATOIRES FOURNIER SA (FR) 2003-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060084699-A1 Novel arylsulphonamide derivatives and use thereof as therapeutic agents UGT1A1, UGT2B7, UGT1A6 SLC1A3 2972/4885SLC1A2 3044/4885LMNA 4632/4885
US-20110015185-A1 Benzofuran Compounds HTR6, HTR1F, HTR1A SLC1A3 1118/4885SLC1A2 534/4885LMNA 1896/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.